Clinical trial · Observational
CML Pediatric ITK Response According to Molecular Identification at Diagnosis
CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML Piramid
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitor (TKI). Nevertheless, case of failure and suboptimal response are still observed even in children. Pediatric CML is a rare disease and differs from adult in terms of disease presentation and treatment response underlying a likely different CML biology. Molecular mechanisms that induce resistance to TKI are still poorly characterized except mutations in the tyrosine kinase domain of BCR::ABL1. We propose to search for a molecular signature to predict the response to TKI in the pediatric population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next Generation Sequencing (DNA and RNA) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Responders (with CCR at 1 year)
- interventionNames
- Biological: Next Generation Sequencing (DNA and RNA)
- label
- No responders (without CCR at 1 year)
- interventionNames
- Biological: Next Generation Sequencing (DNA and RNA)
Primary outcomes (1)
- measure
- Complete cytogenetic response (CCR)
- timeFrame
- At 12 months from TKI start
- description
- We will analyse the impact of the presence of mutations on the obtention of CCR
Secondary outcomes (6)
- measure
- Molecular response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age at diagnosis less than or equal to 18 years * Presence of a Philadelphia chromosome detected by cytogenetic analysis (conventional karyotype or Fluorescence In Situ Hybridization (FISH)) and a BCR ::ABL1 transcript e13a2 ou e14a2 * Diagnosis in chronic phase according to the European Leukemia Net (ELN) criteria * First-line treatment with TKIs * Possible pre-treatment with hydroxyurea * DNA available at diagnosis * RNA available for a sub-group patients (8 responders vs 8 no responders) Exclusion Criteria: * Age at diagnosis more than 18 years * Diagnosis in accelerated phase or blastic phase * First line treatment other than TKI
References
Publications (0)
Data not yet available